Clinical Trial Readiness for SCA1 and SCA3

Investigator: Tetsuo Ashizawa, MD

Study Coordinator: Valerie Flores

Status: Enrolling Number: NCT03487367

Phone: 713.363.9803

Protocol Number: Pro00017836


The investigators plan to fill the gap between the current state of clinical trial readiness and the optimal one for SCA1 and SCA3, which are fatal rare diseases with no treatments. Through US-European collaborations, the investigators will establish the world's largest cohorts of subjects at the earliest disease stages, who will benefit most from treatments, validate an ability to detect disease onset and early progression by imaging markers, even prior to ataxia onset, and identify clinical trial designs that will generate the most conclusive results on treatment efficacy with small populations of patients.
More to Explore